Eupraxia Pharmaceuticals (EPRX) Competitors $3.03 -0.16 (-5.02%) (As of 04:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EPRX vs. CYRX, DSGN, PROC, BTMD, NGNE, VYGR, CTNM, SLRN, KMDA, and TRVIShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Cryoport (CYRX), Design Therapeutics (DSGN), Procaps Group (PROC), biote (BTMD), Neurogene (NGNE), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Cryoport Design Therapeutics Procaps Group biote Neurogene Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Trevi Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do insiders and institutionals hold more shares of EPRX or CYRX? 92.9% of Cryoport shares are owned by institutional investors. 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor EPRX or CYRX? In the previous week, Cryoport had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Cryoport and 1 mentions for Eupraxia Pharmaceuticals. Cryoport's average media sentiment score of 1.46 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in EPRX or CYRX? Cryoport received 239 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 65.05% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesCryoportOutperform Votes24265.05% Underperform Votes13034.95% Do analysts rate EPRX or CYRX? Eupraxia Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 197.03%. Cryoport has a consensus price target of $12.29, suggesting a potential upside of 58.73%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher valuation & earnings, EPRX or CYRX? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Cryoport. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.72-4.21Cryoport$226.11M1.69-$99.59M-$3.38-2.29 Is EPRX or CYRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Cryoport -70.08%-13.35%-6.43% SummaryCryoport beats Eupraxia Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad ProsperityPubAre you ignoring this trading opportunity?$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.66M$6.66B$5.01B$8.96BDividend YieldN/A3.07%4.84%4.06%P/E Ratio-4.2110.54132.3417.00Price / SalesN/A194.471,119.49115.39Price / CashN/A57.1640.6638.38Price / Book101.005.104.724.70Net Income-$28.22M$152.09M$118.82M$225.32M7 Day Performance-10.36%-4.11%12.88%-2.77%1 Month Performance-7.06%-3.78%10.60%2.96%1 Year PerformanceN/A9.46%30.05%15.80% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.2584 of 5 stars$3.03-5.0%$9.00+197.0%N/A$82.66MN/A-4.2129Gap DownCYRXCryoport3.1429 of 5 stars$7.53-2.1%$12.50+66.0%-49.9%$372.22M$226.11M-2.321,170Analyst ForecastShort Interest ↓Positive NewsGap UpDSGNDesign Therapeutics0.793 of 5 stars$6.43+14.8%$7.00+8.9%+128.0%$364.07MN/A-7.1840Positive NewsPROCProcaps Group1.189 of 5 stars$3.21+33.2%N/A+3.8%$362.15M$414.10M5.105,500Trading HaltedHigh Trading VolumeBTMDbiote3.2725 of 5 stars$6.63+4.1%$9.11+37.4%+20.0%$360.25M$193.06M24.77194Analyst ForecastNGNENeurogene3.7733 of 5 stars$24.03+2.2%$60.83+153.2%N/A$356.97M$925,000.000.0090VYGRVoyager Therapeutics4.5879 of 5 stars$6.50+3.7%$17.00+161.5%-27.8%$355.10M$250.01M8.83100Gap UpCTNMContineum Therapeutics1.4092 of 5 stars$13.56-3.3%$29.25+115.7%N/A$349.58M$50M0.0031News CoverageSLRNAcelyrin2.7489 of 5 stars$3.42+5.9%$11.75+243.6%-55.1%$343.13MN/A-1.31135KMDAKamada3.893 of 5 stars$5.84-0.5%$14.50+148.3%-3.2%$335.68M$158.38M20.96360Positive NewsTRVITrevi Therapeutics3.5218 of 5 stars$4.34+4.1%$9.31+114.6%+221.7%$333.62MN/A-10.2020Gap UpHigh Trading Volume Related Companies and Tools Related Companies Cryoport Competitors Design Therapeutics Competitors Procaps Group Competitors biote Competitors Neurogene Competitors Voyager Therapeutics Competitors Contineum Therapeutics Competitors Acelyrin Competitors Kamada Competitors Trevi Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EPRX) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
